Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Receives Average Recommendation of “Moderate Buy” from Brokerages

Lexeo Therapeutics, Inc. (NASDAQ:LXEO) has been assigned an average recommendation of “Moderate Buy” from the nine research firms that are covering the firm, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, seven have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month price target among brokers that have issued a report on the stock in the last year is $18.8750.

A number of research analysts have recently commented on the company. Chardan Capital restated a “buy” rating and issued a $17.00 target price on shares of Lexeo Therapeutics in a research note on Monday, May 11th. Weiss Ratings upgraded Lexeo Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, May 15th. Finally, Wall Street Zen upgraded Lexeo Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, May 16th.

Insider Transactions at Lexeo Therapeutics

In other Lexeo Therapeutics news, CEO Richard Nolan Townsend sold 55,000 shares of Lexeo Therapeutics stock in a transaction on Monday, April 6th. The stock was sold at an average price of $5.69, for a total transaction of $312,950.00. Following the completion of the transaction, the chief executive officer owned 340,106 shares in the company, valued at approximately $1,935,203.14. The trade was a 13.92% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 59,644 shares of company stock worth $336,462 in the last three months. 5.30% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the stock. 683 Capital Management LLC raised its stake in Lexeo Therapeutics by 21.4% during the fourth quarter. 683 Capital Management LLC now owns 1,120,000 shares of the company’s stock valued at $11,122,000 after buying an additional 197,338 shares during the last quarter. Avoro Capital Advisors LLC purchased a new position in Lexeo Therapeutics during the fourth quarter valued at $32,769,000. ProShare Advisors LLC purchased a new position in shares of Lexeo Therapeutics in the fourth quarter worth $146,000. Allworth Financial LP raised its stake in shares of Lexeo Therapeutics by 1,002.9% in the fourth quarter. Allworth Financial LP now owns 3,386 shares of the company’s stock worth $34,000 after purchasing an additional 3,079 shares during the last quarter. Finally, UBS Group AG raised its stake in shares of Lexeo Therapeutics by 12.5% in the fourth quarter. UBS Group AG now owns 281,083 shares of the company’s stock worth $2,791,000 after purchasing an additional 31,174 shares during the last quarter. Hedge funds and other institutional investors own 60.67% of the company’s stock.

Lexeo Therapeutics Stock Up 0.6%

LXEO opened at $5.14 on Wednesday. The stock has a market cap of $403.60 million, a PE ratio of -3.54 and a beta of 1.52. The business has a 50 day moving average of $5.82 and a 200-day moving average of $7.45. Lexeo Therapeutics has a 52 week low of $2.51 and a 52 week high of $10.99.

Lexeo Therapeutics (NASDAQ:LXEO) last released its earnings results on Monday, May 11th. The company reported ($0.25) EPS for the quarter, beating analysts’ consensus estimates of ($0.29) by $0.04. Equities analysts anticipate that Lexeo Therapeutics will post -1.19 EPS for the current year.

Lexeo Therapeutics Company Profile

Lexeo Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to developing novel, precision‐designed therapies for central nervous system disorders. The company’s research platform leverages advanced medicinal chemistry to create next‐generation psychedelic-inspired compounds aimed at treating a range of mental health conditions, including anxiety, depression and substance use disorders.

The company’s pipeline features proprietary synthetic molecules engineered to target specific neural pathways while improving safety and tolerability profiles over traditional treatments.